Education
About Us
Working with TipRanks
Follow Us
RegenXBio (RGNX)
NASDAQ:RGNX
RGNX Stock Chart & Stats
$8.57
-$0.26(-3.11%)
At close: 4:00 PM EST
$8.57
-$0.26(-3.11%)
Day’s Range― - ―
52-Week Range$5.04 - $16.19
Previous CloseN/A
Volume155.59K
Average Volume (3M)1.00M
Market Cap
$442.32M
Enterprise Value$659.89M
Total Cash (Recent Filing)$230.07M
Total Debt (Recent Filing)$260.52M
Price to Earnings (P/E)―
Beta2.31
Next Earnings
May 06, 2026EPS Estimate
-1.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.30
Shares Outstanding51,612,984
10 Day Avg. Volume1,144,050
30 Day Avg. Volume1,001,094
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)7.23
Price to Sales (P/S)4.36
P/FCF Ratio-5.88
Enterprise Value/Market Cap1.49
Enterprise Value/Revenue3.87
Enterprise Value/Gross Profit7.32
Enterprise Value/Ebitda-4.53
Forecast
1Y Price Target
$30.60Price Target Upside257.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-2.15
Revenue Forecast (FY)$243.39M
Bulls Say, Bears Say
Bulls Say
Commercial Readiness And Regulatory PlanningCommercial-scale manufacturing of RGX-202 and plans to request a pre-BLA meeting with the FDA position the company to advance quickly toward a biologics license application if clinical evidence supports approval.
Funding And Partnership SupportA multi-year cash runway, committed funding from AbbVie, and outperformance in licensing and royalty revenues reduce near-term financing pressure and help sustain development through key milestones.
Pivotal Clinical ReadoutsPivotal topline data for the RGX-202 Duchenne program and Phase 3 sura-vec wet age-related macular degeneration trials could support regulatory approvals and materially expand commercial opportunity if those readouts are positive.
Bears Say
Clinical Data Variability And Sample SizeSubstantial variability across patients and limited sample sizes in interim data increase uncertainty about treatment effectiveness and make it harder to build confidence before pivotal results.
Financial Performance And Execution RiskSizable annual net losses underscore heavy dependence on successful clinical outcomes to drive future profitability, amplifying execution and financing risk if programs falter.
Regulatory Setbacks And Clinical HoldsComplete response letters and clinical holds tied to tumor findings in related programs create meaningful regulatory uncertainty that could delay reviews and dampen investor sentiment.
RegenXBio News
RGNX FAQ
What was RegenXBio’s price range in the past 12 months?
RegenXBio lowest stock price was $5.04 and its highest was $16.19 in the past 12 months.
What is RegenXBio’s market cap?
RegenXBio’s market cap is $442.32M.
When is RegenXBio’s upcoming earnings report date?
RegenXBio’s upcoming earnings report date is May 06, 2026 which is in 52 days.
How were RegenXBio’s earnings last quarter?
RegenXBio released its earnings results on Mar 05, 2026. The company reported -$1.3 earnings per share for the quarter, missing the consensus estimate of -$0.956 by -$0.344.
Is RegenXBio overvalued?
According to Wall Street analysts RegenXBio’s price is currently Undervalued.
Does RegenXBio pay dividends?
RegenXBio does not currently pay dividends.
What is RegenXBio’s EPS estimate?
RegenXBio’s EPS estimate is -1.34.
How many shares outstanding does RegenXBio have?
RegenXBio has 51,612,984 shares outstanding.
What happened to RegenXBio’s price movement after its last earnings report?
RegenXBio reported an EPS of -$1.3 in its last earnings report, missing expectations of -$0.956. Following the earnings report the stock price went down -4.595%.
Which hedge fund is a major shareholder of RegenXBio?
Currently, no hedge funds are holding shares in RGNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RegenXBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.60 (257.06% Upside)
$30.60 (257.06% Upside)
Blogger Sentiment
Bullish
RGNX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 162.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.5%
Last 30 Days ▲ 12.7%
Last 30 Days ▲ 12.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
30.83%
12-Months-Change
Fundamentals
Return on Equity
-103.12%
Trailing 12-Months
Asset Growth
-2.78%
Trailing 12-Months
Company Description
RegenXBio
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
RGNX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted multiple strong development and commercial catalysts: completed pivotal enrollment in Duchenne with differentiated efficacy and safety signals for RGX-202, substantial progress and promising outcomes in the Cirovec retinal programs (including large reductions in anti-VEGF injections and durable responses), an active AbbVie collaboration with a near-term $100M milestone, and solid revenue/financing transactions that support a runway into early 2027. Offsetting these positives are material regulatory setbacks in the MPS programs (CRL and clinical holds) driven by an AAV integration–associated tumor in one patient and biomarker/assay issues, plus higher R&D spend and reliance on milestone/monetization proceeds. Overall, the company appears to have multiple high-value, late-stage assets and funding pathways, but faces meaningful program-specific safety and regulatory risks that will need to be resolved.View all RGNX earnings summariesRGNX Stock 12 Month Forecast
Average Price Target
$30.60
▲(257.06% Upside)
Technical Analysis
Solid Biosciences
―
Monopar Therapeutics Inc
―
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
9.42% Insiders
19.07% Mutual Funds
8.85% Other Institutional Investors
48.40% Public Companies and Individual Investors